192 related articles for article (PubMed ID: 25356157)
1. Salmeterol combined with fluticasone propionate improved COPD in patients during stable stage.
Lu D; Ma J; Yang X
Int J Clin Exp Med; 2014; 7(9):2907-11. PubMed ID: 25356157
[TBL] [Abstract][Full Text] [Related]
2. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.
Vogelmeier C; Paggiaro PL; Dorca J; Sliwinski P; Mallet M; Kirsten AM; Beier J; Seoane B; Segarra RM; Leselbaum A
Eur Respir J; 2016 Oct; 48(4):1030-1039. PubMed ID: 27492833
[TBL] [Abstract][Full Text] [Related]
4. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
Jarvis B; Markham A
Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
[TBL] [Abstract][Full Text] [Related]
5. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
Donohue JF; Worsley S; Zhu CQ; Hardaker L; Church A
Respir Med; 2015 Jul; 109(7):870-81. PubMed ID: 26006754
[TBL] [Abstract][Full Text] [Related]
6. Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease.
Fenton C; Keating GM
Drugs; 2004; 64(17):1975-96. PubMed ID: 15329047
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
Agustí A; de Teresa L; De Backer W; Zvarich MT; Locantore N; Barnes N; Bourbeau J; Crim C
Eur Respir J; 2014 Mar; 43(3):763-72. PubMed ID: 24114969
[TBL] [Abstract][Full Text] [Related]
8. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.
Donohue JF; Kalberg C; Emmett A; Merchant K; Knobil K
Treat Respir Med; 2004; 3(3):173-81. PubMed ID: 15219176
[TBL] [Abstract][Full Text] [Related]
9. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
[TBL] [Abstract][Full Text] [Related]
10. Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial.
Singh D; Worsley S; Zhu CQ; Hardaker L; Church A
BMC Pulm Med; 2015 Aug; 15():91. PubMed ID: 26286141
[TBL] [Abstract][Full Text] [Related]
11. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
[TBL] [Abstract][Full Text] [Related]
12. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
Schermer TR; Albers JM; Verblackt HW; Costongs RJ; Westers P
Fam Pract; 2007 Apr; 24(2):181-8. PubMed ID: 17251178
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and safety of transdermal tulobuterol in the treatment of stable COPD: an open-label comparison with inhaled salmeterol.
Fukuchi Y; Nagai A; Seyama K; Nishimura M; Hirata K; Kubo K; Ichinose M; Aizawa H;
Treat Respir Med; 2005; 4(6):447-55. PubMed ID: 16336029
[TBL] [Abstract][Full Text] [Related]
14. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
Jung KS; Park HY; Park SY; Kim SK; Kim YK; Shim JJ; Moon HS; Lee KH; Yoo JH; Lee SD; ;
Respir Med; 2012 Mar; 106(3):382-9. PubMed ID: 21975275
[TBL] [Abstract][Full Text] [Related]
15. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.
Paggiaro PL; Dahle R; Bakran I; Frith L; Hollingworth K; Efthimiou J
Lancet; 1998 Mar; 351(9105):773-80. PubMed ID: 9519948
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
[TBL] [Abstract][Full Text] [Related]
17. Additive effects of salmeterol and fluticasone or theophylline in COPD.
Cazzola M; Di Lorenzo G; Di Perna F; Calderaro F; Testi R; Centanni S
Chest; 2000 Dec; 118(6):1576-81. PubMed ID: 11115442
[TBL] [Abstract][Full Text] [Related]
18. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
Appleton S; Smith B; Veale A; Bara A
Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
[TBL] [Abstract][Full Text] [Related]
19. Genetic effects on efficacy to fluticasone propionate/salmeterol treatment in COPD.
Condreay LD; Qu XA; Anderson J; Compton C; Ghosh S
Respir Med; 2019 Aug; 155():51-53. PubMed ID: 31299468
[TBL] [Abstract][Full Text] [Related]
20. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
